Pharmacological and Neuromodulatory Treatments for Suicidality: A 2026 Updated Review
This 2026 review examines pharmacological and neuromodulatory treatments for suicidality, framed through the "brake and accelerator" model of neural circuitry and inflammatory dysregulation. It highlights evidence for lithium in bipolar disorder, clozapine in schizophrenia spectrum disorders, rapid-acting (es)ketamine, and electroconvulsive therapy, advocating precision approaches distinguishing acute crisis relief from long-term risk reduction in personalized suicide prevention care.
CitationHide citation
Medeiros, G. C., Baruzzi, M. M., Beiram, L., Roncete, G. P., de Figueiredo, L. L., Nery, L. de D. M., Cacciacarro, M. F., Zanetti, M. V., & Damiano, R. F. (2026). Pharmacological and neuromodulatory treatments for suicidality: A 2026 updated review. Psychiatric Annals, 56(5), e115–[end page not visible]. https://doi.org/10.3928/00485713-20260313-05